Silent hypoxia in COVID-19: pathomechanism and possible management strategy

Mol Biol Rep. 2021 Apr;48(4):3863-3869. doi: 10.1007/s11033-021-06358-1. Epub 2021 Apr 23.

Abstract

The novel coronavirus disease 2019 (COVID-19) has become a severe health issue, especially to the patients who develop silent hypoxia condition after SARS-CoV-2 infection. Due to the lack of dyspnoea and extremely low oxygen saturation level, these patients are at exceptionally higher risk. Although the prevalence of silent hypoxia in COVID-19 patients has been evident in several cases, the underlying pathomechanism behind this condition is still unclear. Silent hypoxia in SARS-CoV-2 infected patients can be diagnosed with the help of a pulse oximeter, blood gas levels, and a 6-min walking test. While the clinicians and researchers figure out the exact reason for this phenomenon, the patients must be under strict day-to-day monitoring. In this article, we aim to provide comprehensive insights into the underlying symptoms, mechanism, and possible factors behind the occurrence of silent hypoxia among COVID-19 patients.

Keywords: COVID-19; Dyspnoea; Management; Pathomechanism; Silent hypoxia.

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme 2 / metabolism
  • Blood Gas Analysis
  • COVID-19 / diagnosis*
  • COVID-19 / immunology
  • COVID-19 / metabolism
  • COVID-19 / pathology*
  • Humans
  • Hypoxia / diagnosis
  • Hypoxia / metabolism
  • Hypoxia / pathology
  • Hypoxia / virology
  • Hypoxia-Inducible Factor 1 / metabolism
  • Oximetry
  • Practice Guidelines as Topic

Substances

  • Hypoxia-Inducible Factor 1
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2